FDA approves new type of therapy to treat advanced urothelial cancer

(December 19, 2019)

Today, the U.S. Food and Drug Administration granted accelerated approval to Padcev (enfortumab vedotin-ejfv), a Nectin-4-directed antibody and microtubule inhibitor conjugate, meaning the drug specifically targets cancer cells – in this case, the cell... Continue Reading

FDA Grants Accelerated Approval to Brukinsa for Mantle Cell Lymphoma

(December 5, 2019)

Continued approval may be contingent upon verification of clinical benefit in a confirmatory trial The Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib; BeiGene USA) for the treatment of adult patients with... Continue Reading

Superior Overall Survival for Opdivo (nivolumab) Plus Low-Dose Yervoy (ipilimumab) compared Chemotherapy in Advanced Non-Small Cell Lung Cancer

(November 29, 2019)

The Opdivo plus low-dose Yervoy immunotherapy combination improved long-term survival for patients with advanced non-small cell lung cancer (NSCLCC) across PD-L1 expression levels. (3) Both Opdivo and Yervoy are effective for the treatment of many... Continue Reading

Alunbrig Continues to Demonstrate Superiority in the First – Line After Two Years of Follow-Up for ALK + NSCLC

(November 27, 2019)

Updated data released 11/2019 from the Phase 3 ALTA-1L clinical trial evaluating Alunbrig (brigatinib) versus Xalkori (crizotinib) in patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) who had not received... Continue Reading

PARP Inhibitor + Avastin Delays Cancer Progression When Used as Initial Treatment for Ovarian Cancer

(October 9, 2019)

Maintenance therapy with the PARP inhibitor Lynparza (olaparib) added to Avastin (bevacizumab) resulted in a significant and clinically meaningful delay in cancer progression in patients with advanced stage III-IV ovarian cancer  according to the... Continue Reading

E-Cigarette Smoke Causes Lung Cancer in Mice

(October 8, 2019)

Exposure to e-cigarette smoke caused mice to develop lung cancer, a new study finds. Published online October 7 in Proceedings of National Academy of Sciences (PNAS), the study found that 9 of 40 mice (22.5 percent) exposed to e-cigarette smoke with... Continue Reading

Tagrisso Improves Overall Survival in EGFR-Mutation Positive NSCLC

(October 4, 2019)

Initial treatment with Tagrisso (osimertinib) significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer (NSCLC), according to results of the FLAURA... Continue Reading

Addition of Avastin to Tarceva Doesn’t Improve Outcome in EGF-Positive NSCLC

(September 27, 2019)

Progression-free survival (PFS) rates with erlotinib therapy plus bevacizumab for EGFR-positive non–small-cell lung cancer (NSCLC) were not superior to those seen with erlotinib monotherapy, according to findings from a phase 2 clinical trial. In the... Continue Reading

Monitoring of Symptoms More Important Than Blood Counts in Polycythemia Vera

(September 24, 2019)

A recent study supports what individuals with polycythemia vera (PV) have known for years. PV associated symptoms are underappreciated by doctors and don’t necessarily correlate with blood counts levels. Individuals with PV can experience symptoms... Continue Reading

Ask the Expert About Treatment of Advanced Colon Cancer

(September 23, 2019)

Dr. Tanios Bekaii- Saab, MD, Program Head Mayo Clinic answered questions about management of advanced colo-rectal cancer CancerConnect and The Personalized Medicine Foundation were pleased to provide patients and caregivers the opportunity to ask questions... Continue Reading

Keytruda plus Lenvima Approved for Certain Patients with Uterine Cancer

(September 19, 2019)

The United States Food and Drug Administration (FDA) granted accelerated approval to the combination of Keytruda (pembrolizumab) and Lenvima (lenvatinib) for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability... Continue Reading

Flumatinib Shows Promise in Chronic-Phase Chronic Myeloid Leukemia

(September 3, 2019)

Flumatinib may be more effective than Gleevec (imatinib) for initial treatment of chronic phase-chronic myeloid leukemia (CML-CP) according to study results presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Chronic... Continue Reading

Next Page »